EcoDrugPlus

Mitogen-Activated Protein Kinase 9

Ensembl ID : ENSSMAG00000003397
Gene Symbol: MAPK9
2 Cross references
210 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 1

Ensembl ID : ENSSMAG00000014654
Gene Symbol: MAP2K1
3 Cross references
214 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 2a

Ensembl ID : ENSSMAG00000011095
Gene Symbol: MAP2K2A
3 Cross references
212 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 2b

Ensembl ID : ENSSMAG00000002878
Gene Symbol: MAP2K2B
1 Cross references
200 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 10

Ensembl ID : ENSSMAG00000013747
Gene Symbol: MAP3K10
2 Cross references
182 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 11

Ensembl ID : ENSSMAG00000014828
Gene Symbol: LOC118300016
2 Cross references
182 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSSMAG00000012938
Gene Symbol: MAP3K12
1 Cross references
185 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 13

Ensembl ID : ENSSMAG00000010180
Gene Symbol: SI:CH211-45C16.2
2 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 5

Ensembl ID : ENSSMAG00000003253
Gene Symbol: MAP3K5
2 Cross references
203 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 8

Ensembl ID : ENSSMAG00000003241
Gene Symbol: MAP3K8
3 Cross references
200 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 9

Ensembl ID : ENSSMAG00000010260
Gene Symbol: MAP3K9
1 Cross references
193 Possible Orthologues:

Monoglyceride Lipase

Ensembl ID : ENSSMAG00000010655
Gene Symbol: MGLL
3 Cross references
208 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).